|
 |
|
|
Claus Receives Susan B. Komen Foundation Grant to Study Women Diagnosed
with Breast Ductal Carcinoma In-Situ and mutations in BRCA1/2
| |
 |
| |
Elizabeth B. Claus, M.D., Ph.D., Associate Professor in the Division of Biostatistics at the Yale School of Public Health has been awarded a two-year, $250,000 grant to study outcomes for women diagnosed with breast ductal carcinoma. |
Dr. Elizabeth B. Claus, Associate Professor at the Yale School of Public
Health, has been awarded a two-year, $250,000 grant from the Susan B. Komen
Foundation to study how outcomes for women diagnosed with breast ductal
carcinoma in-situ (DCIS), a non-invasive form of breast cancer, differ for
women with and without mutations in BRCA1/2, two genes associated with an
increased risk of breast and ovarian cancer.
At present, few women with DCIS
have been tested for disease-associated mutations in BRCA1/2 although
a recent study conducted by Dr. Claus and her colleagues found that women
diagnosed with DCIS are as likely to carry mutations in BRCA1/2 as are
women diagnosed with invasive breast cancer.
“The total number of women
with DCIS and who have been found to have BRCA1/2 mutations is small and no
one research center has a sufficient number of patients for study,” stated
Dr. Claus. In order to gather a group of female BRCA1/2 carriers diagnosed
with DCIS, Claus plans to combine data from a number of other cancer centers,
including the University of Pennsylvania, Dana-Farber Cancer Institute, and
Memorial-Sloan Kettering, in an effort to define preliminary estimates of
outcome and to better define treatment goals for these women.
|
